Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.250
-0.080 (-2.40%)
Nov 13, 2026, 10:01 AM EST - Market open
Recursion Pharmaceuticals Market Cap
Recursion Pharmaceuticals has a market cap or net worth of $2.03 billion as of November 13, 2026. It is the 6,417th most valuable company in the world and the 1,726th biggest in the United States. Its market cap has decreased by 16.42% in one year.
Market Cap
2.03B
Enterprise Value
1.55B
1-Year Change
-16.42%
Global Rank
Country Rank
#1,726 United States
Category
ChartMarket Cap Chart
Since April 16, 2021, Recursion Pharmaceuticals's market cap has decreased from $5.08B to $2.03B, a decrease of -60.08%. That is a compound annual growth rate of -15.17%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 13, 2026 | 2.03B | -4.83% |
| Dec 31, 2025 | 2.13B | -20.16% |
| Dec 31, 2024 | 2.67B | 24.83% |
| Dec 29, 2023 | 2.14B | 46.15% |
| Dec 30, 2022 | 1.46B | -49.51% |
| Dec 31, 2021 | 2.89B | -42.96% |
| Apr 16, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| NewAmsterdam Pharma Company | 2.32B |
| Vir Biotechnology | 2.28B |
| Zymeworks | 2.23B |
| Biohaven | 2.20B |
| Aurinia Pharmaceuticals | 2.20B |
| Vera Therapeutics | 2.19B |
| Immunome | 2.19B |
| First Tracks Biotherapeutics | 2.18B |